NewGenIvf Group Limited Class A Ordinary Shares (NIVF)vsNovartis AG ADR (NVS)
NIVF
NewGenIvf Group Limited Class A Ordinary Shares
$0.69
-18.56%
HEALTHCARE · Cap: $1.77M
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1196963% more annual revenue ($56.58B vs $4.73M). NIVF leads profitability with a 209.0% profit margin vs 23.9%. NIVF trades at a lower P/E of 0.0x. NIVF earns a higher WallStSmart Score of 58/100 (C).
NIVF
Buy58
out of 100
Grade: C
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NIVF.
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 79 in profit
Keeps 209 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of -349.1%
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : NIVF
The strongest argument for NIVF centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 209.0% and operating margin at -349.1%. Revenue growth of 11.9% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : NIVF
The primary concerns for NIVF are EPS Growth, Market Cap, Operating Margin.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
NIVF profiles as a mature stock while NVS is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
NIVF is growing revenue faster at 11.9% — sustainability is the question.
Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NIVF scores higher overall (58/100 vs 49/100), backed by strong 209.0% margins and 11.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NewGenIvf Group Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
NewGenIvf Group Limited (NIVF) is a prominent player in the reproductive health sector, specializing in innovative fertility solutions and advanced in vitro fertilization (IVF) services. With a commitment to enhancing success rates in assisted reproductive technology, NIVF is well-positioned to capitalize on the growing global demand for fertility treatments, supported by an extensive network of clinics and strategic partnerships. As the fertility services market continues to evolve, NIVF is positioned for considerable growth, dedicated to empowering individuals and couples in their journey to parenthood.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?